HK1010988A1 - Method for reproducing in vitro the proteolytic activity of the ns3 protease of hepatitis c virus (hcv) - Google Patents

Method for reproducing in vitro the proteolytic activity of the ns3 protease of hepatitis c virus (hcv)

Info

Publication number
HK1010988A1
HK1010988A1 HK98111982A HK98111982A HK1010988A1 HK 1010988 A1 HK1010988 A1 HK 1010988A1 HK 98111982 A HK98111982 A HK 98111982A HK 98111982 A HK98111982 A HK 98111982A HK 1010988 A1 HK1010988 A1 HK 1010988A1
Authority
HK
Hong Kong
Prior art keywords
ns4a
pct
hcv
protease activity
reproducing
Prior art date
Application number
HK98111982A
Other languages
English (en)
Inventor
Raffaele De Francesco
Cristina Failla
Licia Tomei
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Publication of HK1010988A1 publication Critical patent/HK1010988A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK98111982A 1994-02-23 1998-11-13 Method for reproducing in vitro the proteolytic activity of the ns3 protease of hepatitis c virus (hcv) HK1010988A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM940092A IT1272179B (it) 1994-02-23 1994-02-23 Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
PCT/IT1995/000018 WO1995022985A1 (en) 1994-02-23 1995-02-14 Method for reproducing in vitro the proteolytic activity of the ns3 protease of hepatitis c virus (hcv)

Publications (1)

Publication Number Publication Date
HK1010988A1 true HK1010988A1 (en) 1999-07-02

Family

ID=11402272

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98111982A HK1010988A1 (en) 1994-02-23 1998-11-13 Method for reproducing in vitro the proteolytic activity of the ns3 protease of hepatitis c virus (hcv)

Country Status (15)

Country Link
US (1) US5739002A (de)
EP (1) EP0746333B1 (de)
JP (1) JP3280384B2 (de)
AT (1) ATE179611T1 (de)
AU (1) AU691259B2 (de)
BR (1) BR9506931A (de)
CA (1) CA2182521C (de)
DE (1) DE69509504T2 (de)
DK (1) DK0746333T3 (de)
ES (1) ES2132644T3 (de)
GR (1) GR3030166T3 (de)
HK (1) HK1010988A1 (de)
IT (1) IT1272179B (de)
RU (1) RU2149185C1 (de)
WO (1) WO1995022985A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767233A (en) * 1995-05-12 1998-06-16 Schering Corporation Soluble cleavable substrates of the hepatitis C virus protease
US5843752A (en) * 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease
IT1278077B1 (it) * 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
JPH11513890A (ja) * 1996-05-10 1999-11-30 シェーリング コーポレイション Ｃ型肝炎ウイルスｎｓ３プロテアーゼの合成インヒビター
US5990276A (en) * 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
EP1364961B1 (de) * 1996-09-12 2006-11-22 Vertex Pharmaceuticals Incorporated Kristallisierbare Zusammensetzungen, die einen Komplex von Protease-Domäne NS3 und NS4A aus dem Hepatitis C Virus enthalten, und damit bereitgestellte Kristalle
US6153579A (en) * 1996-09-12 2000-11-28 Vertex Pharmaceuticals, Incorporated Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
US5861297A (en) * 1996-09-27 1999-01-19 Merck & Co., Inc. Detergent-free hepatitis C protease
AU4904397A (en) * 1996-10-17 1998-05-11 Chiron Corporation Protease regulator screening assay
WO1998037180A2 (en) * 1997-02-22 1998-08-27 Abbott Laboratories Hcv fusion protease and polynucleotide encoding same
US6251583B1 (en) 1998-04-27 2001-06-26 Schering Corporation Peptide substrates for HCV NS3 protease assays
US6280940B1 (en) 1998-08-05 2001-08-28 Agouron Pharmaceuticals, Inc. Reporter gene system for use in cell-based assessment of inhibitors of the Hepatitis C virus protease
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
WO2000040707A1 (en) * 1999-01-08 2000-07-13 Bristol-Myers Squibb Co. Modified forms of hepatitis c virus ns3 protease
CA2376965A1 (en) * 1999-07-07 2001-01-11 Timothy Patrick Forsyth Peptide boronic acid inhibitors of hepatitis c virus protease
WO2001038538A1 (en) * 1999-11-23 2001-05-31 Viropharma Incorporated Polymerase compositions and methods of use thereof
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
ATE461207T1 (de) * 2000-07-21 2010-04-15 Schering Corp Peptide als inhibitoren der ns3-serinprotease des hepatitis c virus
AR029851A1 (es) * 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
WO2002008187A1 (en) * 2000-07-21 2002-01-31 Schering Corporation Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
EP1423522A2 (de) * 2001-01-23 2004-06-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus-replikons und replikon- verbesserte zellen
WO2003026589A2 (en) * 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
ATE467680T1 (de) 2001-10-11 2010-05-15 Merck Sharp & Dohme Hepatitis-c-virus-impfstoff
DE60236364D1 (en) 2001-10-11 2010-06-24 Angeletti P Ist Richerche Bio Hepatitis-c-virus-impfstoff
DE60326831D1 (en) 2002-04-16 2009-05-07 Merck & Co Inc Hepatitis-c-virus-testsysteme
CA2514918C (en) * 2003-02-13 2012-07-03 Merck & Co., Inc. Method to confer cell culture replication activity to different hepatitis c virus isolates
US7414031B2 (en) * 2004-11-22 2008-08-19 Genelabs Technologies, Inc. 5-nitro-nucleoside compounds for treating viral infections
WO2006093986A1 (en) * 2005-02-28 2006-09-08 Genelabs Technologies, Inc. Tricyclic-nucleoside prodrugs for treating viral infections
US7834145B2 (en) * 2005-03-22 2010-11-16 Merck Sharp & Dohme Corp. HCV protease substrates
AR056327A1 (es) * 2005-04-25 2007-10-03 Genelabs Tech Inc Compuestos de nucleosidos para el tratamiento de infecciones virales
BRPI0612124A2 (pt) * 2005-06-24 2010-10-19 Genelabs Tech Inc derivados de heteroarila para o tratamento de viroses
CA2627247C (en) * 2005-10-28 2013-04-02 Boehringer Ingelheim International Gmbh Hepatitis c virus ns2/3 activity assay
WO2007145894A2 (en) 2006-06-08 2007-12-21 Merck & Co., Inc. A rapid method to determine inhibitor sensitivity of ns3/4a protease sequences
RU2009105837A (ru) * 2006-07-20 2010-08-27 СмитКлайн Бичем Копэрейшн (US) Полициклические противовирусные соединения (варианты), фармацевтическая композиция на их основе, способ лечения вирусной инфекции с ее помощью и названные соединения для изготовления лекарственных средств
US20100216161A1 (en) * 2009-02-26 2010-08-26 Vertex Pharmaceuticals Incorporated Method for identifying protease inhibitors
WO2008112108A1 (en) 2007-03-09 2008-09-18 Merck & Co., Inc. In vivo hcv resistance to anti-viral inhibitors
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
WO2009029729A1 (en) * 2007-08-31 2009-03-05 Genelabs Technologies, Inc. Amino tricyclic-nucleoside compounds, compositions, and methods of use
AR082453A1 (es) 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
EP2595983A1 (de) 2010-07-22 2013-05-29 Novartis AG 2,3,5-trisubstituierte thiophenverbindungen und ihre verwendung
WO2012092484A2 (en) 2010-12-29 2012-07-05 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
WO2014139587A1 (en) 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
WO2017025782A1 (en) 2014-09-17 2017-02-16 Glaxosmithkline Biologicals Sa Improved poxviral vaccines
US11965191B2 (en) 2018-01-18 2024-04-23 California Institute Of Technology Programmable protein circuits in living cells
US10899823B2 (en) 2018-01-18 2021-01-26 California Institute Of Technology Programmable protein circuits in living cells
US11453893B2 (en) 2018-08-30 2022-09-27 California Institute Of Technology RNA-based delivery systems with levels of control
US11542305B2 (en) 2018-08-31 2023-01-03 California Institute Of Technology Synthetic protein circuits detecting signal transducer activity
EP3908653A4 (de) 2019-01-10 2022-11-02 California Institute of Technology Synthetisches system zur abstimmbaren schwellenwertbildung von proteinsignalen

Also Published As

Publication number Publication date
ATE179611T1 (de) 1999-05-15
ITRM940092A0 (it) 1994-02-23
IT1272179B (it) 1997-06-16
JP3280384B2 (ja) 2002-05-13
AU1822395A (en) 1995-09-11
DE69509504D1 (de) 1999-06-10
US5739002A (en) 1998-04-14
WO1995022985A1 (en) 1995-08-31
GR3030166T3 (en) 1999-08-31
EP0746333B1 (de) 1999-05-06
DK0746333T3 (da) 1999-11-01
BR9506931A (pt) 1997-09-09
AU691259B2 (en) 1998-05-14
ES2132644T3 (es) 1999-08-16
RU2149185C1 (ru) 2000-05-20
ITRM940092A1 (it) 1995-08-23
DE69509504T2 (de) 1999-09-02
EP0746333A1 (de) 1996-12-11
CA2182521C (en) 1999-07-06
JPH10500005A (ja) 1998-01-06
CA2182521A1 (en) 1995-08-31

Similar Documents

Publication Publication Date Title
GR3030166T3 (en) Method for reproducing in vitro the proteolytic activity of the ns3 protease of hepatitis c virus (hcv)
RU96119350A (ru) Способ репродукции in vitro протеолитической активности ns3 протеазы вируса гепатита c(нсу)
NZ283995A (en) Customized (mutant) carboxypeptidase Y having modified S1 subsite
AU8843701A (en) Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof
WO2001002601A3 (en) Cell-based assay systems for examining hcv ns3 protease activity
ES2193144T3 (es) Compuestos de dna que comprenden secuencias que codifican manuronano c-5-epimerasa.
PT846164E (pt) Metodologia para produzir, purificar e analisar polipeptidos com a actividade proteolitica da protease hcv ns3
MX9708679A (es) Sustratos disociables, solubles de la proteasa del virus de la hepatitis c.
MY113378A (en) Dictyostelium dipeptidylaminopeptidase
O'CONNELL et al. A 13C-NMR study of the role of Asn-155 in stabilizing the oxyanion of a subtilisin tetrahedral adduct
MXPA05003713A (es) Metodo de purificacion de lantibioticos.
JPS6437298A (en) Production of c-terminal amidated peptide
AU5069800A (en) Novel gbv sequence
GB0006537D0 (en) Assays and screening methods
ATE236990T1 (de) Verfahren zur herstellung von optisch aktiven alpha-aminonitrilen
EP0316907A3 (en) Enzyme inhibitor and method of producing the same
Bianchi et al. Substrate specificity and mechanism of activation of hepatitis C virus protease
Dang Thrombin and the Na (+)-induced allostery in serine proteases

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140214